Scarica l'app Stockscreener
99.96
0.31%
0.31
Dopo l'orario di chiusura:
99.96
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché LNTH Giù?
Forum
Previsione
Lantheus Holdings Inc Borsa (LNTH) Ultime notizie
Halper Sadeh LLC is Investigating Whether ITGR, FHB, INDV, LNTH are Obtaining Fair Deals for their Shareholders - GlobeNewswire Inc.
CMS Grants Transitional Pass-Through Payment Status to Lantheus (LNTH) PYLARIFY TruVu Injection - GuruFocus
Starting Oct. 1, Lantheus's prostate cancer scan qualifies for separate Medicare payment in hospital outpatient care. - Stock Titan
Lantheus Holdings, Inc. (LNTH) Stock Price, News, Quote & History - Yahoo! Finance Canada
Total equity of Lantheus Holdings Inc – HAN:0L8 - TradingView
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: SoundThinking, Inc. (Nasdaq – SSTI), Lantheus Holdings Inc. (Nasdaq – LNTH), MarketAxess Holdings Inc. (Nasdaq – MKTX), Sangoma Technologies Corpor - mykxlg.com
Lantheus Investor Asks Court To Halt 'Unfair' $8B Curium Deal - Law360
Lantheus doses first patient in prostate cancer imaging trial By Investing.com - Investing.com Australia
Lantheus (LNTH) Begins Patient Dosing in SPARROW Trial for Prost - GuruFocus
Lantheus doses first patient in prostate cancer imaging trial - Investing.com
A patient receives an experimental prostate cancer scan; the later phase is expected to enroll about 400. - Stock Titan
Form 13D/A Perspective Therapeutics For: 26 September By Investing.com - Investing.com India
Lantheus Holdings (LNTH) Could Be 7% Undervalued On BRAVNETSA Approval - Yahoo Finance
LNTH Stock Drops After-Hours As Curium's $7B Offer Comes In Below Market Value - Stocktwits
Lantheus Holdings (LNTH) Stock May Be 14% Undervalued On FDA Approval - Yahoo Finance
Lantheus stock trades at USD 99.72 after FDA approval - AD HOC NEWS
FDA approves Lantheus’ Bravnetsa for GEP-NETs - dotmed.com
FDA approval for Lantheus’ Bravnetsa - The Pharma Letter
Lantheus Holdings, Inc. (LNTH) Stock Forecasts - Yahoo! Finance Canada
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Werewolf Therapeutics, Inc. (Nasdaq – HOWL), Beazer Homes USA, Inc. (NYSE – BZH), Lantheus Holdings Inc. (Nasdaq – LNTH), MarketAxess Holdings Inc. ( - The Daily Tribune News
Curium Resets FTC Clock On $8B Lantheus Take-Private Deal - Law360
After selling nearly 1.4 million shares in one day, a Perspective Therapeutics (CATX) holder still has a stake. - Stock Titan
Strong Earnings, FDA Approval, and Takeover Interest Drive Lantheus Holdings’ (LNTH) Rally - Yahoo Finance
3 Reasons LNTH is Risky and 1 Stock to Buy Instead - Yahoo Finance
Lantheus Holdings wins FDA approval for Bravnetsa before Curium vote - Mugglehead Investment Magazine
Lantheus wins final FDA approval for BRAVNETSA (lutetium Lu 177 dotatate( for GEP-NETs - app.dealroom.co
LNTH Looks 11.3% Overvalued on GF Value™ After FDA Approval - GuruFocus
Lantheus Holdings, Inc. Receives Final FDA Approval for BRAVNETSA for Treatment of GEP-NETs - marketscreener.com
Lantheus Says Curium Resubmits Antitrust Filing for Merger - moomoo.com
FDA approves Lantheus’ BRAVNETSA for neuroendocrine tumors By Investing.com - Investing.com Australia
FDA approves Lantheus’ BRAVNETSA for neuroendocrine tumors - Investing.com India
Lantheus Receives Final FDA Approval for BRAVNETSA™ (Lutetium Lu 177 Dotatate), the Only Radiopharmaceutical FDA has Determined to be Bioequivalent and Therapeutically Equivalent to LUTATHERA® for the Treatment of GEP-NETs - marketscreener.com
A radioactive cancer treatment becomes the first approved through the FDA’s abbreviated drug pathway - Stock Titan
The Technical Signals Behind (LNTH) That Institutions Follow - Stock Traders Daily
Lantheus Holdings stock faces a new Curium review window - AD HOC NEWS
LNTH Looks 11.3% Overvalued on GF Value™ - GuruFocus
Lantheus Holdings, Inc. (LNTH) Stock Analysis: A Healthcare Powerhouse with a 7.15% Potential Upside - DirectorsTalk Interviews
Lantheus Holdings, Inc. (LNTH): Investor Outlook On A Potential 7.47% Upside - DirectorsTalk Interviews
(LNTH) Risk Channels and Responsive Allocation - Stock Traders Daily
LNTH, ITGR and CZR Deals Face Investor Scrutiny - stl.news
Lantheus Holdings Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Lantheus Holdings, Inc.LNTH - Business Wire
Perspective Therapeutics (CATX) Insider Sale: 10% Owner Lantheus Alpha Therapy, LLC Sells 247,932 Shares - GuruFocus
Perspective Therapeutics (CATX) holder sells stock near $3.10 - Stock Titan
Lantheus Alpha Therapy Sells 113,914 Perspective Therapeutics (AMEX: CATX) Shares at Up to $3.14 Per Share - Kalkine Media
Lantheus Entities Hold 20.9% Stake in Radiopharm Theranostics (NASDAQ: RADX) Including Significant Options - Kalkine Media
Lantheus Group Reduces Stake in Perspective Therapeutics (AMEX: CATX) to 10% Amid Activist 13D Filing - Kalkine Media
Lantheus Holdings (NASDAQ: LNTH) 10% Stakeholder Alpha Therapy Sells 42,129 Shares at $3.11 Each - Kalkine Media
Lantheus (NASDAQ: LNTH) holders to vote on cash buyout with potential bonus payout - Stock Titan
Radioligand Therapy Market to Grow from USD 2.98 Billion in 2025 to USD 15.85 Billion by 2035, at a CAGR of 18.2% - GlobeNewswire Inc.
Lantheus Holdings, Inc. (LNTH) Stock Analysis: Exploring Growth Potential in the Healthcare Sector - DirectorsTalk Interviews
Lantheus alpha therapy, CATX director, sells $131k in stock By Investing.com - Investing.com Australia
Lantheus alpha therapy, CATX director, sells $131k in stock - Investing.com
Perspective Therapeutics (CATX) Insider Sell: 10% Owner Lantheus Alpha Therapy, LLC Disposes of 42,129 Shares - GuruFocus
Lantheus Holdings (NASDAQ: LNTH) Disposes of 35,769 Perspective Therapeutics Shares at $3.12 Each - kalkinemedia.com
Perspective Therapeutics (CATX) backer trims stake but keeps 11.5M shares - Stock Titan
10% owner of Perspective Therapeutics (NYSE: CATX) sells 113,914 shares over two days - Stock Titan
Perspective Therapeutics (CATX) backer Lantheus now owns 10% after share sales - Stock Titan
1.15%
5.19%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):